| Benefit from Renal Cancer Drug Appears Small - MedPage Today |
|
|
MedPage Today An FDA advisory panel will vote Wednesday on whether the benefits of axitinib (Inlyta) -- small for most patients who failed first-line therapy -- are worth granting approval for the drug in advanced renal |